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Abstract
Hepatitis B virus (HBV) replicates its DNA genome through reverse transcription of a viral
RNA pregenome. We report herein that the interferon (IFN) stimulated exoribonuclease
gene of 20 KD (ISG20) inhibits HBV replication through degradation of HBV RNA. ISG20
expression was observed at basal level and was highly upregulated upon IFN treatment in
hepatocytes, and knock down of ISG20 resulted in elevation of HBV replication and attenua-
tion of IFN-mediated antiviral effect. The sequence element conferring the susceptibility of
HBV RNA to ISG20-mediated RNA degradation was mapped at the HBV RNA terminal
redundant region containing epsilon (ε) stem-loop. Furthermore, ISG20-induced HBV RNA
degradation relies on its ribonuclease activity, as the enzymatic inactive form ISG20D94G
was unable to promote HBV RNA decay. Interestingly, ISG20D94G retained antiviral activity
against HBV DNA replication by preventing pgRNA encapsidation, resulting from a conse-
quence of ISG20-ε interaction. This interaction was further characterized by in vitro electro-
phoretic mobility shift assay (EMSA) and ISG20 was able to bind HBV ε directly in absence
of any other cellular proteins, indicating a direct εRNA binding capability of ISG20; however,
cofactor(s) may be required for ISG20 to efficiently degrade ε. In addition, the lower stem
portion of ε is the major ISG20 binding site, and the removal of 4 base pairs from the bottom
portion of ε abrogated the sensitivity of HBV RNA to ISG20, suggesting that the specificity of
ISG20-ε interaction relies on both RNA structure and sequence. Furthermore, the C-termi-
nal Exonuclease III (ExoIII) domain of ISG20 was determined to be responsible for interact-
ing with ε, as the deletion of ExoIII abolished in vitro ISG20-ε binding and intracellular HBV
RNA degradation. Taken together, our study sheds light on the underlying mechanisms of
IFN-mediated HBV inhibition and the antiviral mechanism of ISG20 in general.
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Author summary
HBV is a DNA virus but replicates its DNA via retrotranscription of a viral RNA prege-
nome. ISG20, an antiviral RNase induced by interferons, inhibits the replication of many
RNA viruses but the underlying molecular antiviral mechanism remains elusive. Since all
the known viruses, except for prions, have RNA products in their life cycles, ISG20 can be
a broad spectrum antiviral protein; but in order to distinguish viral RNA from host RNA,
ISG20 may have evolved to recognize virus-specific signals as its antiviral target. We dem-
onstrated herein that ISG20 selectively binds to a unique stem-loop structure called epsi-
lon (ε) in all HBV RNA species and degrades viral RNA to inhibit HBV replication.
Because ε is the HBV pregenomic RNA packaging signal and reverse transcription prim-
ing site, the binding of ISG20 to ε, even in the absence of ribonuclease activity, results in
antiviral effect to prevent DNA replication due to preventing viral polymerase binding to
pgRNA. We also determined the structure and sequence requirements of ε RNA and
ISG20 protein for ISG20-ε binding and antiviral activity. Such information will aid the
function study of ISG20 against viral pathogens in host innate defense, and ISG20 has
potentials to be developed into a therapeutic agent for viral diseases including hepatitis B.
Introduction
Hepatitis B virus (HBV) infection remains a significant health threat to humans, leading to the
elevated rate of severe liver diseases, such as fulminant hepatitis, fibrosis, cirrhosis, primary
hepatocellular carcinoma, and other clinical complications [1].
HBV is the prototype member of hepadnaviridae family which contains a number of DNA
viruses replicating their genome through reverse transcription of a viral RNA intermediate in
hepatocytes. After cell infection mediated by the viral receptor, called sodium taurocholate
cotransporting polypeptide (NTCP) [2], the 3.2kb relaxed circular (rc) viral DNA genome in
the virion enters the nucleus and transforms into a nucleosome-decorated covalently closed
circular (ccc) DNA minichromosome. Using cccDNA as transcription template, five viral
mRNAs are transcribed from different transcription initiation sites but all terminated at a
same polyadenylation site, which are, 3.5~3.6 kb precore mRNA, 3.5 kb pregenomic (pg)
RNA, 2.4 and 2.1 kb surface (envelope) mRNA, and 0.7kb X mRNA. Besides serving as the
template for translation of viral core protein and polymerase (pol), the pgRNA is also the tem-
plate for reverse transcription. The pol recognizes a stem loop structure (epsilon, ε) at the 5’
terminus of pgRNA to recruit core proteins to encapsidate pol/pgRNA complex into nucleo-
capsid, where the reverse transcription takes place to yield progeny viral rcDNA [3]. Consider-
ing the importance of viral RNA in HBV life cycle, it is conceivable that HBV RNA reduction
will result in a suppression of both viral DNA replication and antigen production. Therefore,
hijacking HBV RNA is believed to be an important antiviral strategy for host defense against
HBV. In line with this, interferons are able to directly reduce HBV RNA through both tran-
scriptional and posttranscriptional mechanisms [4–7]. In terms of interferon-stimulated genes
(ISG), the tripartite motif-containing protein 22 (TRIM22) and DEAD-box RNA helicase
DDX3 have been shown to inhibit HBV RNA transcription [8, 9], and the zinc finger antiviral
protein (ZAP) and myeloid differentiation primary response gene 88 (MyD88) have been
identified as host intrinsic antiviral factors against HBV through promoting the decay of HBV
RNA [10, 11].
In search of ISGs that inhibit HBV replication, we have previously found that the 20 KDa
interferon-stimulated gene product, referred to as ISG20, inhibited HBV replication primarily
Mechanism of ISG20-mediated HBV RNA degradation
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through reducing HBV RNA transcript levels in cell cultures [4]. This protein, which has been
shown to be induced by both type I and type II IFNs, belongs to DEDDh subgroup of the
DEDD exonuclease superfamily. Sequence homologies are distributed at three distinct motifs
termed as ExoI (a.a7-16), ExoII (a.a 86–101) and ExoIII (a.a 147–157) [12]. ISG20 is a 3’ to 5’
exonuclease with the substrate preference of single-stranded RNA over double-stranded RNA
or single-stranded DNA. Its enzymatic activity is mediated by the ExoII motif, as substitution
of the Aspartic acid 94 (D94) in the ExoII motif to Glycine (D94G) completely abolishes its
exonuclease activity [13]. Cellular proteins may be involved in regulation of ISG20 in substrate
recognition and/or binding in order to avoid any non-specific cell toxicity, however which
remain to be identified.
ISG20 has been shown playing an important role in host antiviral innate immune defense
[14]. It is a key ISG against alphavirus replication in host antiviral defense mediated via IFN-α/β
signaling [15]. Cells with overexpressed ISG20 are resistant to the infections of RNA viruses
including vesicular stomatitis virus (VSV), influenza virus, encephalomyocarditis virus (EMCV),
hepatitis A and C virus (HAV and HCV), yellow fever virus, and HIV, but not to a DNA virus,
adenovirus [16–18].
In the context of HBV infection, it has been reported that ISG20 was highly induced during
IFN-mediated suppression of viral replication in HBV transgenic mouse hepatocyte cell lines
[19], and in the liver of acutely HBV infected Chimpanzee during viral clearance phase [20].
Interestingly, chronic hepatitis B patients who had good responses to IFN treatment showed
significantly higher levels of ISG20 in their livers compared to either the patients who were
non-responders to IFN treatment or the healthy controls [21]. All the above findings suggest
that ISG20 may play a role in suppressing HBV in response to host immune activation or IFN-
based immunotherapy.
Therefore, we set out to further characterize the antiviral function and mechanism of ISG20
in innate control of HBV. We report herein that: 1) the endogenous ISG20 is a restriction fac-
tor for HBV replication and it can be upregulated by all three types of IFN to further inhibit
HBV; 2) ISG20 inhibits HBV replication primarily by promoting viral RNA degradation; 3)
ISG20-mediated HBV RNA degradation depends on its ribonuclease activity, but the enzymat-
ically inactivated form retains antiviral activity against pgRNA encapsidation by competing
with HBV pol for pgRNA binding; 4) ISG20 recognizes HBV RNA through directly binding to
the lower stem region of epsilon and the binding domain on ISG20 is located in Exo III motif;
5) ISG20-epsilon binding is essential to ISG20-mediated HBV RNA degradation in cell cul-
tures, and other cofactor(s) may be required for ISG20 to efficiently degrade the stem-loop
region of HBV RNA. Our results thus have impacts on a better understanding of ISG20 biol-
ogy and host-virus interaction, and may provide basis for host ribonuclease-based antiviral
development.
Results
ISG20 basal expression in hepatocytes and induction by IFNs
ISG20 is an interferon inducible protein [16]. Firstly, we assessed the basal expression of
ISG20 in cell cultures and its inducibility by IFN. Using Hela cells as a positive control, the
basal level of ISG20 expression was detected in both HepG2 cells and Huh7 cells by Western
blot, and its expression was significantly upregulated by IFN-α stimulation (Fig 1A). Further-
more, ISG20 can be highly induced by all three types of IFNs in both HepG2 cells and primary
human hepatocytes (PHH) (Fig 1B). According to a previous study on the transcriptional reg-
ulation of ISG20, a unique interferon stimulated response element (ISRE) in the TATA-less
human ISG20 promoter confers IRF-1-mediated constitutive transcriptional activity of ISG20
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gene and responsiveness to both type I and II interferons [22]. The basal and cytokine-induc-
ible expression of intrahepatic ISG20 indicates a potentially important role of ISG20 in host
defense mechanisms against pathogen infections in hepatocytes.
Overexpression of ISG20 inhibits HBV replication in cell cultures
In an effort to determine the antiviral activity of ISG20 against HBV replication in hepatocytes,
FLAG-tagged wild type ISG20 was co-transfected with pHBV1.3 (HBV precore mRNA and
pgRNA transcription is controlled by viral enhancer II and core promoter (EnII/Cp)) or
pCMVHBV (pgRNA transcription is governed by CMV-IE promoter) in HepG2 cells. HBV
viral RNA and DNA were analyzed, as shown in Fig 2A. The result clearly demonstrated that
Fig 1. ISG20 expression in hepatocytes and its inducibility by IFNs. (A) Hela, HepG2, and Huh7 cells
were seeded in a 12-well plate for overnight, then left untreated or treated with human IFN-α (1,000 IU/ml) for
18 or 36 h. The untreated cells (control) were harvested together with the cells treated by IFN-α for 36 h.
ISG20 expression was detected by Western blot. Hela cells transfected with plasmid F-ISG20 expressing the
FLAG-tagged ISG20 were used as positive control for ISG20 Western blot (lane 2). β-actin expression was
presented as loading control. (B) PHHs and HepG2 cells were cultured in 12-well-plate and treated with type I
IFN-α (1,000 IU/ml), type II IFN-γ (100 ng/ml) or type III IFN-λ (100 ng/ml), or left untreated (control) for 2
days. The levels of ISG20 expression were determined by Western blot.
https://doi.org/10.1371/journal.ppat.1006296.g001
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ISG20 markedly inhibited HBV DNA replication (middle panel) primarily through reducing
the steady state levels of 3.5kb viral pgRNA (top panel) which is the template for HBV DNA
synthesis, and such effect is independent of promoter (HBV EnII/Cp or CMV-IE) used to
transcribe the pgRNA. A similar antiviral effect of ISG20 was also observed in Huh7 cells (Fig
2B). Furthermore, the ISG20-mediated pgRNA reduction is dose dependent (S1 Fig) and not
due to a possible cytotoxicity effect caused by ISG20 overexpression (S2 Fig). In addition,
along with pgRNA reduction, the levels of 2.4 kb and 2.1 kb HBV surface mRNA, which share
100% sequence identity with the 3’ portion of pgRNA, were also reduced upon ISG20 expres-
sion (Fig 2, top panels). The reduction of HBV 2.4/2.1 kb RNA by ISG20 was further con-
firmed by co-transfection of ISG20 and plasmid pLMS expressing HBV subgenomic surface
mRNA in HepG2 cells (S3A Fig). Consistent with ISG20-mediated reduction of 3.5 kb and
Fig 2. ISG20 overexpression reduces HBV replication in hepatocyte-derived cells. (A) HepG2 cells were
co-transfected with either pHBV1.3 and F-ISG20 or empty vector, or pCMVHBV and F-ISG20 or empty vector, as
indicated. Cells were harvested at day 5 post-transfection, and the levels of viral RNA and DNA were determined
by Northern (top) and Southern (middle) blot hybridization, respectively. For RNA analysis, each lane was loaded
with 10 μg of total RNA and probed with a genome-length, plus-strand-specific HBV riboprobe. Ribosomal RNAs
(28S and 18S) are presented as loading controls. The positions of HBV pgRNA (3.5kb) and subgenomic surface
RNAs (2.4kb and 2.1kb) are indicated. For DNA analysis, HBV core DNA was probed with genome-length,
minus-strand-specific HBV riboprobe. The positions of relaxed circular (RC) and single-stranded (SS) DNAs are
indicated. The relative pgRNA, sRNA or total DNA replicative intermediate level in each sample is expressed as
the percentage of RNA or DNA of the cells transfected with empty vector. ISG20 overexpression was confirmed
by Western blot using monoclonal antibodies against FLAG-tag. β-actin expression was presented as protein
loading control (bottom panels). (B) The same experiment was done in Huh7 cells with pHBV1.3 as HBV
expression vector.
https://doi.org/10.1371/journal.ppat.1006296.g002
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2.4/2.1 kb HBV RNA, the levels of supernatant HBeAg and HBsAg were also significantly
decreased (S3B Fig).
ISG20 reduces HBV RNA by promoting RNA degradation
Considering that HBV plasmid DNA is the viral transcription template in the transfection sys-
tem, it is possible that ISG20 reduces HBV RNA through destabilizing the transfected HBV
plasmid DNA, or by blocking the nuclear import of input plasmid. To test these possibilities,
we recovered the HBV plasmid DNA from the transfected cells by Hirt DNA extraction, fol-
lowed by Dpn I digestion and Southern blot analysis. The result showed that the levels of input
HBV plasmid DNA recovered from whole cells were equal in the absence or presence of
ISG20, as revealed by Dpn I-digested fragments (S4A Fig, top panel). Furthermore, while
ISG20 overexpression reduced HBV core DNA replication in cytoplasm, it did not affect the
level of remaining cytoplasmic HBV plasmid DNA (S4A Fig, middle panel), further confirm-
ing that ISG20 does not alter the stability and distribution of the input HBV plasmid. In addi-
tion, ISG20 transfection in HBV stable cell line HepDES19 cells also resulted in the reduction
of HBV RNA, which were transcribed from the integrated HBV DNA (S4B Fig). Collectively,
these results clearly exclude any negative effect of ISG20 on the stability of HBV RNA tran-
scription template, which is consistent with the reported inability of ISG20 to degrade double
stranded DNA substrate in vitro [13].
Next, in order to determine whether ISG20-mediated down-regulation of HBV RNA via
transcriptional or posttranscriptional mechanism, we first assessed the potential effect of
ISG20 on viral promoter activity. As shown in S5 Fig, the luciferase reporter assays demon-
strated that ISG20 did not significantly affect the activities of HBV Enhancer II/Core (EnII/
Cp) promoter, S2 promoter, or CMV-IE promoter, but even enhanced HBV S1 promoter
activity. Therefore, it is unlikely that ISG20 reduces HBV RNA through inhibiting viral pro-
moter activity at the transcriptional level.
We then compared the decay kinetics of HBV RNA in the absence and presence of ISG20
overexpression. Briefly, ISG20 expression vector or control empty vector was transfected into
the inducible HBV stable cell line HepDES19 cells in the absence of tetracycline (tet) to induce
HBV pgRNA transcription and ISG20 expression; 36 h later, tet was added back to shut down
the de novo pgRNA transcription from the transgene, and after that, the levels of HBV RNA at
different time points were analyzed by Northern blot (Fig 3A). The representative Northern
blot demonstrated that the levels of HBV RNA in HepDES19 cells overexpressing ISG20 at
each time point were less than that in the control group, suggesting that ISG20 promotes HBV
RNA degradation. This is consistent with the previous observations that ISG20 functions as
the 3’-5’ riboexonuclease to degrade single-stranded viral RNA genomes [14, 16]. It is worth
noting that not every HBV RNA-containing HepDES19 cells were transfected by ISG20, there-
fore, the actual effect of ISG20 on HBV RNA stability ought to be stronger than observed in
this experiment. To further quantitatively validate the observed enhancement of HBV RNA
degradation by ISG20, we transfected HepG2 cells with tetracycline-inducible HBV expression
vector pTREHBVDES and plasmid pTet-off expressing the tetracycline-responsive transcrip-
tional activator (tTA), together with either control vector or ISG20 plasmid. In this way, both
HBV RNA and ISG20 coexisted in same cells. Four days later, similarly to the above experi-
ment in HepDES19 cells, tetracycline was added back to block new round of pgRNA transcrip-
tion, and the time course HBV RNA level was quantified by qPCR. As shown in Fig 3B, the
regular half-life of intracellular HBV RNA was approximately 6 h, which is consistent with pre-
vious measurements [10, 23], but the decay kinetics of HBV RNA was much faster in cells
transfected with ISG20, of which the HBV RNA half-life was much less than 3 h, suggesting
Mechanism of ISG20-mediated HBV RNA degradation
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Fig 3. ISG20 promotes HBV RNA degradation in cell cultures. (A) HepDES19 cells were seeded in 35
mm-dish and cultured with tet-free medium to induce HBV pgRNA transcription. 24 h later, cells were
Mechanism of ISG20-mediated HBV RNA degradation
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that ISG20 promotes HBV RNA decay. Hence, we conclude that ISG20-mediated HBV RNA
reduction is primarily through downregulation of HBV RNA stability.
Antiviral effect of endogenous ISG20 on HBV infection
There is a basal level of ISG20 expression in hepatocytes and that could be further induced by
interferons (Fig 1). It was therefore of interest to assess the antiviral activity of endogenous
ISG20 against HBV infection under its basal and induced levels. Firstly, we performed the test
in HBV stable cell line HepDES19 [24]. As shown in Fig 4, knock down of ISG20 expression in
the absence of IFN-α treatment resulted in a marked upregulation of the steady state levels of
HBV total RNA, encapsidated pgRNA, and DNA (comparing lane 4 to lane l). The observed
relatively greater upregulation of core DNA than viral RNA upon knock down of ISG20 might
be due to the longer lifespan of DNA. When the cells were treated with IFN-α, ISG20 was
upregulated, and viral RNA and DNA were reduced, in an IFN dose-dependent manner (lanes
1–3). It is worth to note that the IFN-elicited reduction of HBV RNA in HepDES19 cells was
less profound than in HBV-transfected cells with ISG20 overexpression (compared Fig 4 to Fig
2). Such difference might be due to the reported weak response of hepatoma cells to IFN treat-
ment [25], and/or the potential unknown negative regulator(s) of ISG20 co-induced by IFN.
Nonetheless, in the cells treated with IFN-α and ISG20 siRNA, the levels of HBV RNA were
restored to the untreated control level (comparing lanes 5 and 6 to lanes 1–3), suggesting that
ISG20 plays a major role in IFN-mediated reduction of HBV RNA in HepDES19 cells. How-
ever, neither viral RNA nor DNA reached their levels in cells treated with ISG20 siRNA only
(comparing lanes 5 and 6 to lane 4), indicating that other ISGs are involved in IFN-mediated
suppression of HBV DNA replication at multiple steps.
Next, we assessed the antiviral function of ISG20 in an HBV in vitro infection system, spe-
cifically, the viral receptor NTCP reconstituted HepG2 cells [26]. The endogenous ISG20 in
HepG2-NTCP12 cells was stably inhibited through lentiviral shRNA transduction. The
obtained ISG20 knock down cell line and control knock down cell line were then infected with
HBV and treated with or without IFN-α. As shown in Fig 5A, the basal ISG20 expression was
successfully knocked down in HepG2-NTCP12-shISG20 cells (comparing lane 3 to lane1), and
IFN-α significantly upregulated ISG20 expression in the HepG2-NTCP12-shcontrol cells
(comparing lane 2 to lane1), but only slightly induced ISG20 in the HepG2-NTCP12-shISG20
cells (comparing lane 4 to lane3). Then the outcomes of HBV infection were analyzed. The
HBcAg immunofluorescence staining demonstrated that knock down of ISG20 resulted in a
higher percentage of HBV positive cells when compared to control cells without or with IFN-α
treatment (Fig 5B). Because that the ISG20-mediated HBV RNA degradation will lead to an
overall suppression of the entire HBV life cycle in the infection system, we infer that the
increased percentage of core staining-positive cell number in HBV infected HepG2-NTCP-
shISG20 cells is a combinational end effect of increased viral protein expression, DNA replica-
tion, and cccDNA synthesis, plus the possible higher virus spread rate. Since HBV RNA is a
transfected with 4 μg of control vector or plasmid F-ISG20 for 36 h, then tet was added back to the culture
medium to shut down pgRNA transcription. Cells were harvested at indicated time points. HBV RNA was
extracted from harvested samples and analyzed by Northern blot. Expression of FLAG-tagged ISG20 was
detected by Western blot. The results are representative of three separate trials. (B) HepG2 cells in 12-well-
plate were co-transfected with 0.7 μg of pTREHBVDES and 0.1 μg of pTet-off, plus 0.7 μg of control vector or
plasmid F-ISG20. Four days post transfection, tet was added back and cells were harvested at indicated time
points and subjected to HBV RNA qPCR analysis. The relative levels of HBV total RNA normalized to β-actin
mRNA levels in each samples were expressed as the percentage of the RNA levels from the corresponding
sample at 0 h time point (Mean ± SD, n = 4). The half-life of HBV RNA was marked on the plot.
https://doi.org/10.1371/journal.ppat.1006296.g003
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Fig 4. The antiviral effect of ISG20 in HepDES19 cells under basal expression and IFN-α treatment.
HepDES19 cells were transfected with 100 nM of control siRNA (Lane 1–3) or ISG20 siRNA (siISG20) (lane
4–6) twice with a 24 h interval after tet being withdrawn. Culture medium was replaced 12 h after the 2nd
siRNA transfection, and cells were either left untreated as controls (lane 1 &4) or treated with 100 IU/ml (lanes
2 & 5) or 1,000 IU/ml (lanes 3 & 6) of IFN-α. Cells were harvested 5 days after 2nd transfection. Viral total RNA
(top panel), encapsidated pgRNA (upper middle panel), and core DNA (lower middle panel) were subjected to
Northern and Southern analyses, respectively. ISG20 protein expression was revealed by Western blot, and
β-actin served as loading control (bottom panels). The relative levels of viral nucleic acids and ISG20
Mechanism of ISG20-mediated HBV RNA degradation
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more convincing marker for HBV infection and the authentic antiviral target of ISG20, the
qPCR assay of HBV total RNA from the infected cells further demonstrated that IFN-α is able to
reduce HBV RNA in infected cells, and knocking down of ISG20 greatly favors HBV infection
in both IFN-treated and untreated cells (Fig 5C). Consistent with the observations in HepDES19
cells (Fig 4), inhibition of ISG20 significantly but partially abrogated the overall antiviral activity
of IFN-α in HBV infected cells (Fig 5B and 5C), presumably due to the induction of other antivi-
ral ISGs. Collectively, the above data suggested that ISG20 serves as a host intrinsic restriction
factor to limit HBV infection under both basal expression and cytokine induction.
ISG20-mediated HBV RNA decay depends on its ribonuclease activity
ISG20 has three putative exonuclease domains and it has been reported that a single D94G
mutation in the Exo II domain completely abolished the protein’s enzymatic activity in vitro
[13]. In line with this, we found that the enzymatic inactive mutant F-ISG20D94G failed to
expression in the siISG20 transfected or IFN-α treated samples (lanes 2–6) are expressed as the percentage
of the control sample (lane 1). The data presented here are representative of two independent experiments.
https://doi.org/10.1371/journal.ppat.1006296.g004
Fig 5. The antiviral effect of ISG20 in HBV infection system. HepG2-NTCP12 cells stably transduced by
control lentiviral shRNA (shcontrol) or ISG20 lentiviral shRNA (shISG20) were spinoculated with HBV at 100
vge/cell. 16 h later, the infected cells were mock treated or treated with 1,000 IU/ml of IFN-α for 6 days, and
the cells were subjected to the following analyses: (A) The expression of ISG20 was analyzed by Western
blot. (B) HBV infectivity was assessed by HBcAg immunofluorescence, and the percentage of HBcAg-positive
cells were calculated from multiple microscopic field of view (mean±SD, n = 5). Nuclei were stained with DAPI.
(C) HBV total RNA were quantified by qPCR and the relative expression levels to β-actin mRNA were plotted
as fold change to control samples (HBV infected shcontrol cells without IFN-α treatment) (mean±SD, n = 3).
https://doi.org/10.1371/journal.ppat.1006296.g005
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reduce HBV RNA in HepG2 cells (Fig 6, top panel), suggesting that ISG20-mediated HBV
RNA decay requires its exoribonuclease activity. Interestingly, although the levels of total viral
RNA and capsid remained the same, the level of encapsidated HBV pgRNA was significantly
reduced under the expression of ISG20D94G mutant (middle panel, comparing lanes 5&6 to
1&2), which consequently led to the inhibition of viral DNA replication (bottom panels). The
inhibitory effect of ISG20D94G on pgRNA encapsidation was further confirmed with HBV
genome harboring polymerase Y63D mutation, which supports HBV pgRNA binding and
encapsidation but not DNA replication (S6 Fig)
Since HBV pgRNA encapsidation requires the dynamic interactions among three viral
components, specifically the pgRNA, Pol, and core protein [27], it is possible that ISG20D94G
might be antagonizing one or more of these three viral factors to block encapsidation. How-
ever, ISG20D94G did not inhibit capsid assembly (Fig 6, 3rd panel from the top), and ISG20-
mediated HBV RNA degradation does not rely on viral core or pol protein (S7 Fig). Based on
these data, we hypothesized that ISG20 might physically bind to HBV RNA for degradation,
and thus in the particular case of ISG20D94G, its association with pgRNA inhibited the binding
of HBV polymerase to pgRNA and the subsequent pgRNA encapsidation.
ISG20D94G interacts with HBV RNA and competes Pol-pgRNA binding in
cell cultures
To test the above hypothesis, we first investigated the association between ISG20 and HBV
RNA in cell culture. In this immunoprecipitation (IP)-Northern assay (Fig 7), plasmid pCMV
HBVΔCΔP which supports HBV RNA transcription but does not support pgRNA encapsida-
tion in cis due to the deletion of core and Pol expression was used as HBV RNA transcription
template, and FLAG-tagged HBV Pol (FLAG-Pol) was used in trans as positive control for
pgRNA binding. To avoid the rapid RNA degradation mediated by wild type ISG20 expres-
sion, ISG20D94G mutant was used for this assay. The upper panel of Fig 7 indicates the input
HBV RNA level and FLAG-Pol or F-ISG20D94G protein levels. The lower panel of Fig 7 shows
the Northern blot results after IP with FLAG antibody (Ab). As expected, FLAG-Pol interacted
with HBV RNA, as FLAG Ab, but not the HA Ab, could pull down the HBV RNA. Same as
FLAG-Pol, ISG20D94G also specifically formed complex with HBV RNA in this IP-Northern
assay, suggesting that ISG20 interacts with HBV RNA in cell cultures, though it remains
unknown whether the interaction is direct or indirect.
Next, we set out to investigate the potential competitive effect of ISG20 on Pol-pgRNA bind-
ing. Fixed amount of FLAG-Pol and pCMVHBVΔCΔP were co-transfected into cells together
with plasmid expressing HA-tagged ISG20D94G (HA-ISG20D94G) in a titrated manner. Fig 8
shows the input HBV RNA and FLAG-Pol and HA-ISG20D94G protein levels (upper panels)
and the immunoprecipitated HBV RNA levels after HA or FLAG Ab pull-down (the lower pan-
els). The HA Ab IP-Northern result demonstrated that ISG20D94G bound to HBV RNA in a
dose dependent manner. In contrast, increased amount of ISG20D94G resulted in the decreased
amount of HBV RNA associated with Pol, suggesting that ISG20D94G competes with HBV Pol
for binding of pgRNA and thus inhibits HBV pgRNA encapsidation. It is assumed that the wild-
type ISG20 may possess additional antiviral function as what ISG20D94G does in cells, but the
inhibition of pgRNA encapsidation, if any, will likely be overwhelmed by its dominant primary
effect on RNA degradation.
Mapping the ISG20 responsive elements in HBV RNA genome
The above data demonstrated that ISG20 interacts with HBV RNA. In order to map the
ISG20-targeting sequences, we made use of a series of internal deletion clones and terminal
Mechanism of ISG20-mediated HBV RNA degradation
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Fig 6. The enzymatically inactive form of ISG20 (ISG20D94G) is defective to degrade HBV RNA but
retains antiviral activity against pgRNA encapsidation. HepG2 cells were transfected with pHBV1.3 and
equal amount of control vector (lanes 1 & 2) or F-ISG20 (lanes 3 & 4) or F-ISG20D94G (lanes 5 & 6). Cells were
harvested 5 days post-transfection and levels of HBV RNA (1st panel from the top) and encapsidated pgRNA
Mechanism of ISG20-mediated HBV RNA degradation
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deletion clones of the 3.5kb HBV RNA genome to express truncated RNAs and their sensitivi-
ties to ISG20-mediated RNA degradation were assessed (Fig 9A and S8A Fig). Firstly, we found
that all those pgRNA mutants with internal deletions (within nt 2009-3182/1-1574) were sensi-
tive to ISG20 (S8B Fig). Then the terminal redundancy (TR, nt 1820–1918, containing ε (nt
1849–1909)) mutants with deletion of either 5’ TR (Δ5TR) or 3’ TR (Δ3TR) from pgRNA were
tested. Interestingly, while the single TR deleting pgRNA remained sensitive to ISG20 (Fig 9B,
lanes 1–4), the pgRNA mutant with both 5’ and 3’ TR removed (Δ5/3TR) became completely
resistant (Fig 9B, lanes 5–6), indicating that one copy of the TR sequences is sufficient to confer
the susceptibility of HBV pgRNA to ISG20-mediated RNA degradation. This is also consistent
with the fact that ISG20 is also able to degrade HBV subgenomic RNAs which only contain the
3’ TR (Fig 2 and S3 Fig).
To further confirm that the HBV TR is the ISG20 responsive element, HBV core promoter
activity reporter plasmids EnII/Cp-Luc with TR region inserted at the 5’ (EnII/Cp-TR-Luc),
or 3’ (EnII/Cp-Luc-TR), or both 5’ and 3’ (EnII/Cp-TR-Luc-TR) non-translational region of
luciferase gene (Fig 9C) were transfected into HepG2 cells with or without F-ISG20. The lucif-
erase activities were measured and the result demonstrated that the introduction of HBV TR
into luciferase mRNA resulted in a significant reduction of luciferase gene expression under
ISG20 expression (Fig 9C). Therefore, we conclude that ISG20 selectively targets TR sequences
of HBV RNA to initiate RNA degradation.
ISG20 directly binds to epsilon of HBV TR sequence in vitro
HBV Pol recognizes and binds on a stem-loop structure in 5’ TR region of HBV pgRNA, called
epsilon (ε), to initiate pgRNA encapsidation and reverse transcription [29]. Since ISG20-me-
diated HBV RNA degradation relies on TR sequence (Fig 9) and ISG20D94G competes with
Pol for HBV RNA binding (Fig 8), it is therefore of immediate interest to investigate whether
ISG20 also directly binds on HBV ε to exert its antiviral functions. To this end, an electropho-
retic mobility shift assay (EMSA) was employed. As shown in Fig 10, purified recombinant
His-tagged ISG20 proteins were incubated with 5’ radiolabeled HBV ε RNA in vitro and the
protein/RNA complexes were analyzed via the mobility shifting of the RNA in the native poly-
acrylamide gel. The proper folding of stem-loop structure of ε RNA was confirmed by recom-
binant Pol/ε complex formation as detected in the EMSA assay (S9 Fig). Interestingly, in the
absence of other cellular proteins, His-ISG20 could directly, dose-dependently bind on ε RNA,
shown as the shift bands in Fig 10C (lanes 3, 5, 7), and the binding specificity between His-
ISG20 and ε was confirmed by the His-antibody(Ab) /His-ISG20/ε super-complex formation
detected as a super-shift in EMSA (lanes 4, 6, 8). Competition of ISG20 binding to the radiola-
beled ε RNA by excess amount of cold ε probes indicated again that ISG20 specifically binds
to HBV ε (lanes 9, 10, 11). It is of note that the incubation of ISG20 and ε RNA during EMSA
was performed in protein/RNA binding buffer without manganese, an essential ion for the
enzymatic activity of ISG20 [13], therefore the degradation of ε RNA, if any could occur,
would not be observed in this binding assay.
To further dissect the substructural domain of ε targeted by ISG20, the synthetic upper
stem-loop RNA and the lower stem-loop RNA of ε and their mutants, as shown in the Fig
(4th panel from the top) were determined by Northern blot hybridization. The assembled HBV capsid was
revealed by native capsid gel EIA assay (3rd panel from the top) and the viral DNA in capsid was detected in
situ by hybridization (5th panel from the top). HBV core DNA replicative intermediates were extracted and
analyzed by Southern blot (6th panel from the top). Expression of FLAG-tagged ISG20 proteins was revealed
by Western blot and β-actin served as loading control (bottom two panels). Results from duplicate experiments
are presented.
https://doi.org/10.1371/journal.ppat.1006296.g006
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11A, were radiolabeled and used in gel shift assay. Interestingly, ISG20 bound to the lower
stem with bulge sequence serving as loop, but not the upper stem-loop of ε in EMSA (Fig
Fig 7. ISG20D94G physically associates with HBV RNA in cells. HepG2 cells were co-transfected with
plasmid pCMVHBVΔCΔP and either control vector (lane 1) or FLAG-Pol (lanes 2&3), or pCMVHBV with either
control vector (lane 4) or F-ISG20D94G (lanes 5&6). Cells were harvested 4 days post-transfection. Input HBV
RNA was determined by Northern blot (top panels). Input FLAG-Pol and F-ISG20D94G proteins were determined
by Western blot using FLAG Ab (top panels). Cell lysates were immunoprecipitated with beads coated with
FLAG Ab, the immunoprecipitated Pol and ISG20D94G were revealed by Western blot using FLAG Ab (lanes
3&6, bottom panel), and the bound RNA was extracted by Trizol and analyzed by Northern blot (lanes 3&6,
bottom panel). HA Ab pull-down served as negative controls (lanes 2 & 5, bottom panel). See Material and
Methods for more experimental details.
https://doi.org/10.1371/journal.ppat.1006296.g007
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Fig 8. ISG20D94G competes HBV Pol for binding to pgRNA in cell cultures. HepG2 cells in 6-well-plate
were co-transfected with 1 μg of pCMVHBVΔCΔP and 5 μg control vector (lane 1) or 1 μg of FLAG-Pol in the
absence of HA-ISG20D94G (lane 2) or increased amount of HA-ISG20D94G (1 μg, 2 μg, 4 μg; lanes 3–5). The
total amount of transfected DNA was kept constant (6 μg/well) by adding control vector plasmid (lanes 2–4). 5
days later, total cellular HBV RNA and protein (FLAG-Pol and HA-ISG20D94G) were determined by Northern
and Western blot, respectively, as input controls (top panels). Immunoprecipitation was performed by using
antibodies against HA or FLAG epitopes, followed by Northern blot analysis of HBV RNA (bottom panels).
https://doi.org/10.1371/journal.ppat.1006296.g008
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Fig 9. Mapping the ISG20 responsive elements in HBV genome. (A) Schematic illustration of HBV pgRNA
deletion clones. Plasmid pHBV1.3 contains a 1.3 overlength HBV genome (Genbank Accession Number
U95551), starting at nt 1000. The HBV nucleotide positions are according to Galibert et al [28]. Cp represents
Mechanism of ISG20-mediated HBV RNA degradation
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11B), which indicates that ISG20 recognizes the lower stem and/or bulge of HBV ε as its bind-
ing site. To further determine the binding position within the lower stem and bulge region, the
bulge sequences were mutated or the lower stem were truncated from the bottom (Fig 11A),
and used as probes in EMSA. Interestingly, we found that the loop (or bulge) sequence is not
critical for ISG20 binding as long as the lower stem is intact; however the bottom 4 base-pairs
of the stem is indispensable for ISG20 binding (Fig 11C). To further confirm the requirement
of these 4 base-pairs for ISG20 to carry out its biological functions, we disrupted the base pair-
ing at the bottom of ε stem-loop in HBV 2.1 kb surface mRNA by removing 4 nucleotides
from the 3’ end of ε coding sequence, and found that the mutant RNA became resistant to
the HBV core promoter. pA is the polyadenylation site. The arrow indicates the pgRNA transcription initiation
site (nt 1820). Three major HBV mRNA (3.5 kb, 2.4 kb, and 2.1 kb) are depicted underneath the 1.3 mer HBV
DNA template. The solid dot indicates 5’ cap of mRNA; and the sawtooth line represents the polyA tail at the 3’
terminus of mRNA. The internal deletion clones (pg-IDs) are described in details in S8 Fig. The terminal
redundancy (TR) deletion clones contain truncations of HBV sequences (nt 1820–1918) at either 5’ or 3’
terminus of pgRNA coding sequences (pg-Δ5TR and pg-Δ3TR, respectively.), or both (pg-Δ5/3TR). The
transcription of terminal truncated pgRNA is governed by CMV-IE promoter in the pCDNA3.1/V5-His-TOPO
vector. (B) Sensitivity of HBV RNA with TR deletion to ISG20-mediated RNA reduction. HepG2 cells were
transfected with HBV TR deletion clone and control plasmid or F-ISG20 plasmid. Cells were harvested at day
4 post transfection and subjected to viral RNA analysis by Northern hybridization. (C) HBV TR insertion
renders Luc gene to be sensitive to ISG20. The schematic illustration indicates the reporter construct EnII/Cp-
Luc with HBV TR insertion at the flanking non-translational region of luciferase ORF. HepG2 cells were
transfected with each indicated reporter plasmid and control vector or plasmid expressing ISG20. Cells were
lysed at day 3 post transfection and luciferase activity was measured. The plotted relative luciferase activity
(RLA) represents the mean ± SD (n = 3) of the percentage of absorbance obtained from wells transfected with
ISG20 over control vector.
https://doi.org/10.1371/journal.ppat.1006296.g009
Fig 10. ISG20 binds to HBV ε in vitro. (A) Schematic stem-loop structure of HBV εRNA. Ribonucleotide sequences (nt 1847–1991,
genotype D, subtype ayw) are presented with base paring indicated by dotted line. (B) Verification of the purified recombinant 6×His-tagged
ISG20 by SDS-PAGE Coomassie staining. (C) EMSA assay of ISG20-ε binding. The indicated amount of ISG20 proteins were incubated with
100 ng 32P-end-labeled εRNA in binding buffer to form nucleoprotein complexes. Monoclonal anti-His antibody was used for supershifting of
the His-ISG20/ HBV ε complex. Excessive amount of cold unlabeled HBV εRNA (10×, 20×, 40×) were used to compete with the binding of
ISG20 to 100 ng radiolabeled HBV ε. The nucleoprotein complexes were separated by native PAGE and the shifted bands were detected by
autoradiography.
https://doi.org/10.1371/journal.ppat.1006296.g010
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ISG20-mediated RNA degradation in cell cultures (Fig 11D). Collectively, these findings imply
that ISG20 recognizes sequence-specific secondary structure of HBV ε for RNA binding and
degradation.
Fig 11. ISG20 specifically binds to lower stem of HBV ε. (A) Schematic illustrations of the wildtype HBV εRNA and mutants. The
substructural domains of ε, including the lower stem, bulge, upper stem, and apical loop, are marked on the full-length form. Shorter
versions of ε include the upper stem loop (US+L), lower stem with wildtype or mutant bulge sequence as loop (LS+B, LS+Bm), and LS+B
with bottom 4 base-pairs removed from the lower stem (LSΔ4+B). These RNA fragments were chemically synthesized and 5’ end
radiolabeled for ISG20 EMSA. (B) EMSA of ISG20 binding with full-length (FL) ε, US+L, and LS+B. (C) EMSA of ISG20 binding with LS
+B, LS+Bm, and LS+B. (D) HepG2 cells were transfected with plasmid pMS transcribing the 2.1kb HBV RNA, or pMSΔ4bp transcribing
the 2.1kb HBV with 4 nucleotides removed from the bottom right arm of the lower stem of ε, in the absence or presence of F-ISG20. HBV
RNA and FLAG-tagged ISG20 were analyzed by Northern and Western blot, respectively.
https://doi.org/10.1371/journal.ppat.1006296.g011
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Exo III domain mediates the binding of ISG20 to ε
Since ISG20 is able to bind on its RNA substrate directly in the absence of any other cellular or
viral proteins, it is therefore of interest to investigate which domain of ISG20 is responsible for
RNA binding. Three distinct exonuclease motifs, namely Exo I (a.a7-16), Exo II (a.a 86–101)
and Exo III (a.a 147–157), have been predicted in ISG20 protein sequence from previous stud-
ies [14, 30] (Fig 12A). Based on that, the recombinant mutant ISG20 proteins with each Exo
domain deletion or Exo II D94G mutation were tested for ε binding activity by EMSA. As
shown in Fig 12B and 12C, in comparison to wildtype ISG20, deletion of Exo I or Exo II did
not reduce, but even increased the binding affinity of ISG20 with ε (lanes 2–4); however ISG20
with Exo III deletion completely lost the binding activity (lane 5), indicating that the Exo III is
the functional binding domain of ISG20 for its RNA substrate. In addition, the enzymatically
inactive D94G mutant retains its function for ε binding (lane 6), which is consistent with the
observed association of ISG20D94G with HBV RNA and subsequent inhibition of pgRNA
encapsidation in cells (Figs 6–8). It is worth noting that the ΔExo I and ΔExo II deletion
mutants, as well as the ISG20D94G mutant, exhibited altered mobility compared to wildtype
ISG20 in the gel shift assay (Fig 12C, lane 2 vs. lanes 3, 4, 6). While it is predictable that the
faster mobility of ΔExo I:ε and ΔExo II:ε complexes is likely due to the protein’s lower molecu-
lar weight (MW), the lower shift of ISG20D94G:ε complex is probably because that such RNP
complex exhibits a different structural conformation compared to the ISG20:ε complex.
To confirm the function of Exo III domain for ISG20 activity, the FLAG-tagged ISG20 pro-
tein with a deletion of Exo III domain was expressed in HBV transfected cells. As shown in Fig
12D, while the wildtype ISG20 significantly reduced HBV RNA levels as expected, the
Fig 12. Exo III motif is responsible for ISG20 to bind ε. (A) Schematic illustration of ISG20. The amino acid (a.a) positions are labeled with
numbers. The gray boxes indicate the predicted Exo motifs. The enzymatic mutant site (D94G) is marked with an asterisk. (B) Bacterially
expressed His-tagged ISG20 and mutants were purified and examined by SDS-PAGE Coomassie staining. The asterisk indicates a nonspecific
protein band co-purified with the recombinantΔExoII mutant. (C) EMSA of ε binding by wildtype ISG20 and the indicated mutants. (D) HepG2
cells were co-transfected with pHBV1.3 and control vector or indicated FLAG-ISG20 constructs. HBV RNA and ISG20 proteins were detected
by Northern and Western blot, respectively.
https://doi.org/10.1371/journal.ppat.1006296.g012
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ISG20ΔExoIII mutant was similar to ISG20D94G in inefficiency in reduction of HBV RNA.
Therefore, we conclude that, while ISG20 requires Exo II domain for its enzymatic activity, the
separate Exo III domain is responsible for RNA substrate binding of ISG20, which is a prereq-
uisite for RNA degradation.
Cofactor(s) is required for ISG20 to efficiently degrade εRNA
Lastly, we set out to characterize the enzymatic activity of ISG20 against ε RNA in vitro. The
previous biochemistry study has demonstrated that ISG20 catalyzes RNA degradation in vitro
in a manganese-dependent manner [13]. As shown in Fig 13, under the reaction condition
that supports ISG20 ribonuclease activity [13], a wide spectrum endoribonuclease RNase A
efficiently degraded ε RNA as a positive control (panel A and B, lanes 1–3). However, ISG20
exhibited much less efficiency to degrade the full length ε RNA substrate (panel A and B, lanes
1, 4–5), and other two stem-loop subdomains (US+L, LS+B) (panel A, lanes 6–11), suggesting
that ISG20 alone does not favor RNA with secondary structures for degradation. Such observa-
tion is consistent with a previous study showing that ISG20 operated poorly on double-
stranded regions of RNA substrate in vitro [13]. In line with these, we found that ISG20 was
able to catalyze the degradation of RNA substrate derived from the left arm of ε (panel B, lanes
6–8), which is lack of secondary structures. Furthermore, ISG20 efficiently degraded the sin-
gle-stranded linear 30-mer poly(rA) oligo in vitro (panel B, lane 11), confirming that the
recombinant ISG20 protein used in the assay was enzymatically active. As a control, RNase A
was unable to degrade poly(rA) because it only cleaves RNA string at the 3´ end of pyrimidine
(rC or U) residues (panel B, lane 10) [31]. Since the RNA substrates were 5’ radiolabeled, the
pattern of degradation intermediates generated by ISG20 is consistent with the 3’-5’ exoribo-
nuclease activity of ISG20 (panel B, lanes 7, 8, 11). Collectively, the above in vitro data indicate
that other host cofactor(s) may be required to coordinate with ISG20 for the observed efficient
HBV RNA degradation in cells.
Discussion
In summary, we report here that ISG20 functions as a 3’-5’ exoribonuclease to degrade HBV
RNA, by which serves as an intrinsic host restriction factor for HBV infection. The selectivity
of ISG20 for HBV RNA is determined by a unique viral ribonucleotide string that shapes a
stem-loop structure (ε) which exists in all HBV RNA species. ISG20 directly binds to the lower
stem of ε through the C-terminal Exo III domain, and such protein-RNA interaction, possibly
with the assistance of a host cofactor(s), will lead to the major antiviral action of ISG20, which
is the enzymatic activity dependent HBV RNA degradation. Subsequently, viral protein trans-
lation and DNA replication will be inhibited (Fig 14). In addition, under certain circumstance
that the enzymatic activity of ISG20 could be inhibited (i.e. the ISG20D94G mutant), the bind-
ing of ISG20 to 5’ ε may remain antiviral by competing the binding of viral polymerase with ε
and blocking the subsequent pgRNA encapsidation and reverse transcription.
It is well documented that, during acute HBV infection, the activation of host T-cell
responses plays a pivotal role in clearing virus from hepatocytes via a noncytolytic mechanism,
which is largely attributed to the antiviral and proinflammatory cytokines produced by the
infiltrating immune cells, such as IFN-γ and TNF-α [32, 33]. To date, IFN-α is the only avail-
able immunotherapy for treatment of chronic hepatitis B [34]. Besides serving as an immuno-
modulatory agent to regulate the host adaptive immunity against HBV, the intracellular
antiviral activity of IFN-α is mediated by an array of ISGs. In search of intrahepatic ISGs asso-
ciated with immune clearance of HBV, a growing body of evidence implies that ISG20 may be
involved in IFN mediated inhibition of HBV, including 1) the upregulation of ISG20 in HBV
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Fig 13. ISG20 requires cofactor(s) to efficiently degrade εRNA. 0.1 µg of 5’-radiolabeled synthetic RNA
substrates, specifically (A) the intact ε, upper stem-loop region (US+L), and lower stem with bulge serving as
loop (LS+B); and (B) the intact ε, single-stranded left arm portion of ε, and 30-mer poly(rA), were incubated with
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transgenic mouse hepatocyte cell lines in which the HBV replication was inhibited by IFN
[19]; 2) the elevation of ISG20 level in viral clearance phase of an acutely HBV infected Chim-
panzee [35]; and 3) the upregulation of ISG20 in chronic hepatitis B patients who responded
well to IFN-α therapy [21]. Consistent with the above findings, we found that ISG20 can be
highly induced in hepatocytes in vitro by all three types of interferons, and it plays a significant
role in IFN-α elicited antiviral effects on HBV infection and replication (Figs 1, 4 and 5). Consid-
ering that HBV RNA are essential genetic components for viral replication and gene expression
in its life cycle, upregulation of ISG20 expression by cytokines to eliminate HBV RNA is a very
economical and efficient way in host defense mechanisms. In addition, our study also expands
the antiviral spectrum of ISG20 to a DNA virus. Considering that current HBV therapy with
nucleoside analogues is ineffective against viral protein expression and cannot efficiently pro-
mote HBeAg or HBsAg seroconversion [34], it is thus envisioned that the ISG20-based antiviral
therapy could be developed in the future to reduce both viremia and antigenemia in CHB
patients.
While its cellular function remains elusive, ISG20 has been previously shown to inhibit a
number of RNA viruses, including VSV, influenza viruses, HIV-1, picornaviruses (EMCV,
HAV), and flaviviruses (HCV, WNV, and bovine viral diarrhea virus (BVDV)) [16–18, 36, 37].
The previously reported antiviral effects of ISG20 on these RNA viruses are all dependent on
its exonuclease activity, though the degradation of viral RNA directly catalyzed by ISG20 has
not been experimentally confirmed. However, RNA degradation might not be the only mecha-
nism of ISG20’s antiviral action. For instance, Zhou et al found that ISG20 did not promote
the degradation of a replication-defective HCV RNA genome in Huh7.5 cells [17]; and Qu
et al observed that ISG20 inhibits Influenza A Virus replication through interaction with viral
nucleoproteins [37]. Furthermore, not all the RNA viruses are susceptible to ISG20, as severe
acute respiratory syndrome coronavirus (SARS-CoV) has shown resistance to ISG20 in cell
cultures [17], indicating that there is viral specific factor(s) to determine the antiviral specific-
ity of ISG20. Here, we clearly demonstrated that ISG20 is able to promote HBV RNA degrada-
tion in cell cultures, and such effect is dependent on the protein’s exonuclease activity (Figs 2–
6). During the preparation of this manuscript, Leong et al also reported that ISG20 inhibited
HBV replication in cell cultures and in hydrodynamic injected mouse liver via exoribonu-
clease-dependent degradation of viral RNA, which is largely consistent with our results, but
their study did not touch on the molecular mechanism for the selective targeting of HBV RNA
by ISG20 [38]. In our study, we further mapped the sequence element responsible for ISG20--
mediated HBV RNA degradation to ε region in HBV RNA genome (Figs 7–9), and confirmed
the direct binding of ISG20 to ε in EMSA assay (Fig 10). To the best of our knowledge, this is
the first report revealing that the RNA sequence/structure-specific recognition is required for
ISG20 to degrade its viral RNA substrate. Such characteristic of ISG20 makes it mechanistically
distinct from RNase L, a well-known antiviral ISG that, upon activation, nonspecifically
destroys both viral and cellular RNA in cells [39]. In this regard, ISG20 represents a novel class
of cellular antiviral ISGs, which is reminiscent of the sequence-specific antiviral RNAi system
[40], but ISG20 targets viral RNA directly without the help of small guide RNA.
HBV RNAs are typical mRNAs produced by host RNA polymerase II, all of which possess
5’ cap and a 3’ poly (A) tail similar to cellular mRNAs [41]. Despite of the sequence difference
with host mRNA, the ε is a unique structure signature of HBV RNA, which serves as pgRNA
the indicated amount of RNase A or purified His-ISG20 in nuclease reaction buffer for 15 min, then the
reactions were terminated and the mixtures were fractionated through 10% TBE-Urea denaturing
polyacrylamide gel, and the dried gel was subjected to autoradiography.
https://doi.org/10.1371/journal.ppat.1006296.g013
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Fig 14. The working model of ISG20-mediated antiviral effect on HBV replication. The major viral
intermediates and products at each major HBV replication steps are illustrated. cccDNA (or other HBV
transcription template)-derived 3.5kb RNA (including precore mRNA and pgRNA) and other shorter
subgenomic RNA species (2.4/2.1kb surface mRNA and 0.7kb X mRNA) are aligned to show the location
of ε on different RNA species. The black circle dots indicate the 5’ cap of mRNA, the zigzag lines represent
the polyA tails. ISG20 is shown as a rectangle box and its targeting sites on HBV RNA are indicated by
arrowheads. As a consequence of ISG20-mediated HBV RNA degradation, the illustrations and labels of
viral proteins/antigens, pgRNA encapsidation and DNA replication are shown in gray color schemes. The
solid gray triangles indicate capsid proteins, viral polymerase is shown in an oval shape before ε binding
and then a gray circle dot in the nucleocapsids after pgRNA encapsidation.
https://doi.org/10.1371/journal.ppat.1006296.g014
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packaging signal and the priming site for interacting with viral polymerase [42]. It is thus con-
ceivable that ISG20 recognizes ε as a “non-self” target to initiate its antiviral function. In line
with this, it has been recently reported that host innate sensor RIG-I binds to ε to trigger IFN-
λ production [43]. In addition, we further determined that the bottom 4bp of lower stem of ε
is the minimal responsive element of ISG20, as the removal of such sequence from HBV RNA
made ISG20 lose both the ε binding activity in vitro and HBV RNA reduction effect in cell cul-
tures (Fig 11). These sequence and structure information could serve as a consensus motif to
predict ISG20-responsive RNA elements in other viruses, and perhaps host RNAs as well.
Despite acting as a host antiviral factor, the other potential functions of ISG20 in regulating
host cellular function remain obscure. Since ISG20 targets viral mRNA for destabilization, it is
plausible that they may also alter the stability of certain cellular mRNA to regulate host gene
expression. For example, the observed enhancement of HBV S1 promoter activity by ISG20
may be due to the ISG20-mediated upregulation of host transcription factor(s) required for S1
promoter activity or downregulation of negative regulator(s) of S1 promoter (S5 Fig). This
notion is also supported by previous observations that ISG20-mediated antiviral effect on
HCV was not through inhibition of HCV RNA stability or translation, indicating that ISG20
might degrade the mRNA of a host factor(s) essential for HCV replication [17]. More interest-
ingly, considering that ISG20 favors short RNAs with stem-loop structures for affinity binding,
it is also possible that ISG20 potentially targets host microRNA (miRNA) precursors (pri-
miRNA and pre-miRNA) [44] and long non-coding RNA (lncRNA) [45], which may contain
ε-like stem-loop structures, to regulate miRNA processing and lncRNA stability, respectively.
In addition, it is known that IFNs regulate cellular gene expression primarily at the mRNA
level [46], so it is possible that ISG20, as a IFN-inducible RNase, may partly mediate the action
of IFN through altering the host mRNA stability. We are currently conducting RNA-seq analy-
sis to search for potential host RNA substrates of ISG20.
ISG20 has three predicted exonuclease domains (Exo I-III) with Exo II being validated as
the major enzymatic domain [14]. We found that the catalytic site (D94) in Exo II of ISG20
was essential for HBV RNA reduction, but the ISG20D94G mutant retained RNA binding activ-
ity and inhibited HBV pgRNA encapsidation through competing the binding of HBV poly-
merase to ε (Figs 6–8). Although such antiviral effect may be just minor in the context of
wildtype ISG20-mediated HBV RNA degradation, this serendipitous finding led us to discover
the binding property of ISG20 with HBV RNA (Fig 10). Interestingly, the minimal binding site
on ε for ISG20 is located at the bottom 4bp of the stem-loop (Fig 11), which is dispensable for
HBV polymerase to bind ε [47], indicating that the inhibition of polymerase binding by ISG20
is due to ISG20/ε interaction-induced steric hindrance and/or conformational shift of ε. In
addition, the domain of ISG20 for ε binding was mapped to the Exo III region (Fig 12), sug-
gesting that the substrate interaction and degradation domains of ISG20 are separated. This is
consistent with the reported crystal structure analysis of ISG20, which predicted that the
amino acid composition of Exo II is unfavorable for RNA binding [30]. However, no classical
RNA binding motif was found in the Exo III domain or the entire ISG20 sequence by compu-
tational prediction (http://www.rcsb.org/pdb/protein/Q96AZ6). ISG20 has been shown to
interact with host U1/2/3 small nucleolar RNAs (snoRNAs) [48], which also have stem-loops,
further indicating that ISG20 may possess a novel binding motif for such kind of double
stranded RNA secondary structures including HBV ε.
We have previously identified the host zinc-finger antiviral protein (ZAP) as a restriction
factor of HBV by promoting HBV RNA degradation [10]. ZAP exerts its antiviral activity
against HBV with certain features similar to ISG20, specifically, both ZAP and ISG20 interact
with HBV RNA for RNA degradation in a ε-dependent manner. Since ZAP does not possess
nuclease activity [49], our initial hypothesis was that ZAP might recruit ISG20 to ε for RNA
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degradation. However, co-immunoprecipitation assay did not reveal any detectable associa-
tion between ZAP and ISG20 in the absence or presence of HBV RNA (S10 Fig), indicating
that ZAP and ISG20 work independently to target HBV ε for their antiviral functions, and
host cells have evolved multiple mechanisms to recognize the “non-self” HBV ε as an antiviral
sensing signal.
It is worth to note that ISG20 is a 3’-5’ exoribonuclease and the ε locates near the 3’ end of all
HBV RNAs and there is an additional 5’ copy in precore mRNA and pgRNA [14, 50], we there-
fore speculate that the binding of ISG20 to ε is an initial substrate sensing step, and RNA topol-
ogy changes and/or ISG20 translocation may be requires for subsequent RNA degradation from
3’ end of HBV RNA. In addition, since ISG20 could single-handedly degrade poly(rA) oligo in
the in vitro degradation assay (Fig 13B), whether the poly(A)-specific ribonuclease (PARN) is
required to remove the poly(A) tail in ISG20-mediated HBV mRNA degradation reaction awaits
further investigations. Interestingly, our in vitro RNA degradation assay demonstrated that
ISG20 efficiently degrades single-stranded RNA but not the ε RNA substrate (Fig 13), indicating
that additional host factor(s), likely a RNA helicase, is required to unwind the double-stranded
region of ε for ISG20 to catalyze RNA degradation. Therefore, we have embarked on the identifi-
cation of cofactors in ISG20 degradesome complex by proteomic approach.
Taken together, the phenotypic and mechanistic characterizations of ISG20-mediated anti-
viral effect on HBV replication presented in current study not only shed light on ISG20 biology
and virus-host interaction, but also provide insight into development of ribonuclease-based
antiviral therapy for treatment of hepatitis B.
Materials and methods
Cell cultures, RNAi, and drugs
Human hepatocyte-derived HepG2 and Huh7 cells were maintained in DMEM/F12 medium
(Mediatech) supplemented with 10% fetal bovine serum, 100 U/ml penicillin and 100 μg/ml
streptomycin. HepDES19 cells were maintained in the same way as HepG2, but with the addition
of 1 μg/ml tetracycline (tet) and 400 μg/ml G418 [24]. To initiate HBV replication in HepDES19
cells, tet was withdrawn from the culture medium and the cells were cultured for the indicated
time. Primary human hepatocytes were purchased from Triangle Research Labs and cultured
according to supplier’s protocol. HepG2-NTCP12 cells were maintained as previously described
[26]. Endogenous ISG20 expression in HepG2-NTCP12 cells was stably knocked down by trans-
duction with ISG20 shRNA lentiviral particles (Santa Cruz Biotechnology) per the manufacturer’s
directions. The transduced cells were selected with 3 μg/ml puromycin, the antibiotics-resistant
cells were pooled and expanded into cell line, namely HepG2-NTCP12 shISG20. Control known
down cell line was generated by transduction with control shRNA lentiviral particles (Santa Cruz
Biotechnology) and designated HepG2-NTCP12 shcontrol. Control siRNA and ISG20 siRNA
were purchased from Santa Cruz Biotechnology for transient knock down experiments. Recom-
binant human IFN-α2a, IFN-γ, and IFN-λ1 were purchased from PBL Biomedical Laboratories.
Plasmids for eukaryotic expression
HBV (genotype D, subtype ayw) replication competent plasmids, pHBV1.3 and pCMVHBV, in
which the transcription of viral pgRNA is governed by authentic HBV core promoter and the
human cytomegalovirus immediate-early (CMV-IE) promoter, respectively, were described
previously [4, 10, 51, 52]. The plasmid pTREHBVDES transcribes pgRNA under the control of
tetracycline-inducible CMV promoter, it has been previously used together with plasmid pTet-
off (Clontech) to generate the HepDES19 stable cell line [24]. pHBV1.3ΔC is a 1.3mer HBV
plasmid with mutation of the start codon (ATG to ATA) of core protein open reading frame
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(ORF) [53] (provided by Dr. Robert Lanford). pHBV1.3ΔP is a 1.3mer HBV plasmid with start
codon mutation (ATG to ACG) of pol ORF to abolish pol expression but without changing the
amino acid sequence of the overlapped core protein. Plasmid pCMVHBVΔCΔP contains start
codon mutations of core (ATG to CTG) and pol (ATG to ACG) ORF in pCMVHBV backbone
to block the expression of core and pol, respectively. pCMVHBV-Y63D bears a Y63D substitu-
tion in the reverse transcriptase domain of HBV pol gene to block DNA synthesis but still allows
pgRNA encapsidation [54] (Provided by Dr. Jianming Hu). Plasmid pCMV-FLAG-Pol, which
expresses HBV Pol with three copies of the FLAG epitope at the N terminus by CMV promoter
[55], was provided by Dr. Wang-Shick Ryu and used in cell transfections. Plasmid pcDNA-
3FHP, another HBV polymerase expression construct that expresses a 3×FLAG-tagged HBV
polymerase (HP) under T7 promoter in pcDNA backbone [56], was provided by Dr. Jianming
Hu and used in in vitro translation of 3F-HP. Plasmid pLMS expresses 2.4kb and 2.1kb HBV
surface mRNA under the control of authentic viral surface promoters (S1 and S2) [57] (pro-
vided by Dr. Youhua Xie). Plasmid pMS expresses 2.1kb HBV surface mRNA under the control
of a CMV promoter, and pMSΔ4bp was constructed by removing four nucleotides from the
bottom right arm of the lower stem of ε sequence in pMS. The pgRNA internal deletion clones
(pgID-1 to pgID14) and terminal redundancy (TR) deletion clones (pg-Δ5TR, pg-Δ3TR, pg-Δ5/
3TR), and luciferase reporter plasmids (En/Cp-Luc, S1-Luc, S2-Luc, En/Cp-TR-Luc, En/Cp-
Luc-TR, and En/Cp-TR-Luc-TR) were constructed previously [10].
Plasmids expressing N-terminal FLAG-tagged wildtype ISG20 (F-ISG20) and ISG20D94G
(F-ISG20D94G) under the control of CMV promoter were described previously [36]. F-ISG20Δ
ExoIII was derived from F-ISG20 by deleting the coding sequence for ExoIII domain of ISG20.
Plasmid HA-ISG20D94G that expresses HA-tagged ISG20D94G was constructed by Q5 Site-Directed
Mutagenesis Kit (New England Biolabs) to replace the FLAG-tag sequence in F- ISG20D94G with
HA-tag. Plasmid HA-ZAPS expresses the HA-tagged ZAP-S protein in eukaryotic cells [10].
Cell transfection
Cells seeded in the collagen coated plate were transfected with indicated plasmid(s) or siRNA
by Lipofectamine 2000 (Life Technologies) according to the manufacturer’s directions.
Reporter assay
HepG2 cells in 96-well-plate were transfected with promoter reporter plasmid plus vectors
expressing gene of interest by Lipofectamine 2000. pRL-CMV Renilla luciferase reporter plas-
mid was cotransfected for normalization of transfection efficiency. For each transfection,
empty control plasmid was added to ensure that each transfection receives the same amount of
total DNA (200 ng/well). Three days after transfection, luciferase activities were measured by
the dual luciferase assay kit (Promega) and BioTek Synergy 2 Multi-Mode Reader.
HBV infection and HBcAg immunofluorescence
HepG2-NTCP12 shcontrol and shISG20 cells were spinoculated with HBV virion particles
derived from HepDE19 cells at 100 virus genome equivalent (vge)/cell according to a pub-
lished protocol [26]. Six days post infection, cells were fixed and subjected to HBcAg immuno-
fluorescence as described previously [26].
HBV RNA/DNA analyses
Total cellular RNA, Hirt DNA, cytoplasmic encapsidated HBV pgRNA and core DNA were
extracted as described previously [10, 24, 51, 58, 59].
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For HBV RNA qPCR assay, DNase I-treated total cellular RNA was used to generate cDNA
by SuperScript III Reverse Transcriptase (Life Technologies). Real-time PCR was performed
with SYBR Green Master (Roche) and the LightCycler 96 System (Roche) for detecting HBV
total RNA by using HBV specific primers targeting the 3’ overlapping region of all the HBV
RNA species (forward primer: 5’-ACTCTCTCGTCCCCTTCTCC-3’, reverse primer: 5’-GGT
CGTTGACATTGCAGAGA-3’). The relative expression levels of HBV RNA were normalized
to β-actin from the same samples.
For HBV RNA Northern blot analysis, total cellular RNA or encapsidated pgRNA samples
were resolved in 1.5% agarose gel containing 2.2 M formaldehyde and transferred onto Hybond-
XL membrane (GE Healthcare). For DNA Southern blot analysis, Hirt DNA or HBV core DNA
samples were resolved by electrophoresis into a 1.5% agarose gel and blotted onto Hybond-XL
membrane. Membranes were probed with either α-32P-UTP (800 Ci/mmol, Perkin Elmer)
labeled plus-strand-specific (for Northern blot hybridization) or minus-strand-specific (for
Southern blot hybridization) full-length HBV riboprobe and exposed to a phosphorimager
screen. Hybridization signals were quantified with QuantityOne software (Bio-Rad).
HBV capsid gel assay
The cytoplasmic HBV capsid particles were resolved in native agarose gel by electrophoresis
and transferred onto nitrocellulose membrane, followed by capsid enzyme immunoassay assay
(EIA) using antibodies against core (DAKO) and in situ HBV DNA hybridization as described
previously [60].
Western blot assay
Whole cell lysate samples prepared by Laemmli buffer was resolved in a 4%-12% gradient
SDS-PAGE and proteins were transferred onto Immobilon PVDF-FL membrane (Millipore).
The membranes were blocked with Western Breeze blocking buffer (Life Technologies) and
probed with antibodies against ISG20 [16], FLAG-tag (Sigma, clone M2), HA-tag (Covance,
clone 16B12), or β-actin (Millipore). Bound antibodies were revealed by IRDye secondary anti-
bodies. The immunoblot signals were visualized and quantified with the Li-COR Odyssey
system.
ELISA
HBeAg and HBsAg in culture fluid were detected by HBeAg ELISA kit (Autobio Diagnostics)
and HBsAg ELISA kit (Abazyme) following the manufacturer’s instructions.
ISG20 and HBV RNA co-immunoprecipitation
HepG2 cells were cotransfected with pCMVHBVΔCΔP and control vector, FLAG-tagged wild-
type or D94G mutant ISG20 in 60 mm dishes and maintained for 4 days. The harvested cells
were lysed on ice with cell lysis buffer containing 1% NP-40, 10 mM Tris.HCl (pH 7.5), 1 mM
EDTA, 50 mM NaCl, 8% sucrose, and 1 U/μl of RNasin Plus RNase Inhibitor (Promega). After
centrifugation to remove the cell debris, the clarified cell lysates were incubated with EZview
Red Anti-HA or Anti-FLAG Affinity Gel (Sigma-Aldrich) at 4˚C for 2 h with gentle rotation.
The beads were spun down and resuspended gently with rinse buffer (10 mM Tris.HCl (pH
7.5), 1 mM EDTA, 50 mM NaCl, and 1 U/μl of RNasin Plus RNase Inhibitor) for three times
at 4˚C. The pelleted beads were subjected to RNA extraction with TRIzol, and protein sample
preparation with Laemmli buffer. Immunoprecipitated ISG20 protein and HBV RNA were
analyzed by Western blot and Northern blot assays, respectively. In terms of the RNA binding
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competition assay for ISG20 and HBV Pol, 2 μg of pCMVHBVΔCΔP was cotransfected with
either 1 μg of control vector or 1 μg of pCMV-FLAG-Pol and with increased amount of
HA-ISG20 D94G as indicated in Fig 8. FLAG or HA immunoprecipitation was performed
with the same protocol described above and the associated HBV RNAs were visualized via
Northern blot using 32P radiolabeled HBV RNA specific riboprobe.
Recombinant His-ISG20 proteins expression and purification
The ORF of wildtype ISG20 and ISG20D94G mutant were PCR amplified from plasmid F-ISG20
and F-ISG20D94G, respectively, and cloned into pRSET A prokaryotic expression vector (Thermo
Fisher Scientific) under the T7 promoter at BamHI and EcoRI sites to generate plasmid express-
ing His-tagged ISG20 (His-ISG20) and ISG20D94G (His-ISG20D94G). ISG20 deletion mutant His-
ISG20ΔExoI, His-ISG20ΔExoII, and His-ISG20ΔExoIII were derived from His-ISG20 by using
Q5 Site-Directed Mutagenesis Kit (New England Biolabs) per the manufacture’s protocol. The
protein expression vectors were transformed into Escherichia coli BL21(DE3) pLysS Competent
Cells (Promega) and the cells were propagated with aeration at 37˚C in 0.5 L of SOB broth in
the presence of 100 μg/ml Ampicillin to an A600 of *0.6, followed by adding 1 mM isopropyl-
1-thio-β-D-galactopyranoside (IPTG) to induce protein expression at 37˚C for 3 hours. The
induction of the recombinant proteins were detected via SDS-PAGE and Coomassie staining as
compared to an uninduced control sample.
The aforementioned His-tagged proteins expressed from bacteria were purified using dena-
turing conditions. Briefly, the bacterial pellet was resuspended in 0.1 M Na-phosphate, 0.1 M
Tris-HCl, 6 M Guanidine-HCl, pH 8.0 with fresh 1 mM PMSF and stirred for 2 h at 4˚C to lyse
the cells and solubilize the proteins under denaturing condition. The cell extract was centrifuged
at 12,000×g for 20 min. The supernatant fraction containing soluble protein was incubated in
batch with PerfectPro Ni-NTA Agarose (5PRIME) for 1 h at room temperature. The resin was
washed once with 0.1 M Na-phosphate, 0.1 M Tris-HCl, 6 M Guanidine-HCl, pH 6.3 and two
times with 0.1 M Na-phosphate, 0.1 M Tris-HCl, 6 M Guanidine-HCl, pH 6.3 with additional
20 mM imidazole. The resin was loaded into the supplied purification column, and the protein
was eluted with 0.1 M Na-phosphate, 0. 1M Tris-HCl, 6 M Guanidine-HCl, pH 4.6 and 300
mM imidazole with 1 mM PMSF. The eluted protein was dialyzed against three changes of
1×PBS, 300 mM NaCl, 5% Glycerol with freshly added 1 mM DTT and 0.1 mM PMSF. The sol-
uble proteins were concentrated with Pierce concentrators (9KD cut-off, Thermo Scientific).
Bio-Rad Bradford protein assay and Coomassie staining were used to measure the concentra-
tion and the purity of the proteins.
Electrophoretic mobility shift assay (EMSA)
The synthetic HBV ε RNA fragments shown in S1 Table were dissolved in 1×TE buffer (DEPC
treated) to a concentration of 1 μg/μl and denatured in 80˚C water bath for 5 min, followed by
slow cooling down to room temperature for RNA annealing and secondary structures forma-
tion. HBV ε RNAs were [γ-32P] end-labeling by T4 polynucleotide kinase (New England Bio-
labs) and purified by Quick Spin Sephadex G25 column (Roche).
The indicated amount of ISG20 proteins were incubated with 100 ng 32P-radiolabeled HBV
RNAs in the presence of 20 mM HEPES, 100 mM KCl, 1 mM DTT, 0.5 mg/ml BSA, 10% Glyc-
erol and 0.05 μg/μl poly[dI-dC] at 30˚C for 30 min to form nucleoprotein complexes. 1 μl of
monoclonal anti-polyHistidine antibody (Clone H1029, Sigma) was used for supershifting of
the His-ISG20/ HBV ε complex. 1 μg, 2 μg or 4 μg of cold unlabeled HBV ε RNAs were used
to compete for binding of the ISG20 protein to 100 ng radiolabeled HBV ε. The nucleoprotein
complexes were separated by native 5% PAGE at 200 V in a gel buffer containing 50 mM Tris,
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45 mM Boric acid, 1% (v/v) Glycerol for 2 h in the cold room. The gel was fixed in 10% acetic
acid and 10% methanol, dried, and visualized by autoradiography.
HBV Pol in vitro translation (IVT) and Pol-ε binding
Expression vector pcDNA-3FHP was used to express 3×FLAG tagged HBV Pol (3F-HP) in
TnT Coupled Reticulocyte Lysate System (Promega) by following manufacturer’s instructions.
The control IVT reaction was done with empty pcDNA3.1 vector (Invitrogen). One microliter
of control or 3F-HP IVT sample was mixed with 1 μl of 32 P-radiolabeled ε RNA (100 ng/μl)
and 18 μl of TMNK RNA binding buffer (20 mM Tris [pH 7.5], 2 mM MgCl2, 15 mM NaCl,
20 mM KCl, and 4 mM DTT) which has been previously used for HBV pol:ε RNA binding
reaction [61]. Then 1% Halt protease inhibitor cocktail (ThermoFisher), 4 μl of RNasin RNase
inhibitors (Promega), and 6 μg of yeast tRNA were added and the binding reaction was incu-
bated at 30˚C for 1 h. The pol:ε binding complex was revealed by EMSA as described above.
In vitro RNA degradation assay
The ribonuclease assay was performed according to previously published reaction conditions
for ISG20 [13]. Briefly, the synthetic RNA oligos (S1 Table) were pretreated as described above
to allow secondary structure formation before purification and 5’-32P labeling. 100 ng of radio-
labeled RNA substrates were incubated with RNase A (New England Biolabs) or purified
recombinant His-ISG20 in 10 μl nuclease assay buffer (50 mM HEPES-KOH (pH 7.0), 10%
glycerol, 50 mM NaCl, 1 mM MnCl2, 0.01% Triton X-100, and 1 mM DTT) at 37˚C for 15
min. The reactions were stopped with 10 μl of an 80% Formamide dye solution, and the mix-
tures were heated at 80˚C for 3 min and then fractionated in Novex 10% TBE-Urea denaturing
polyacrylamide gel (ThermoFisher), and the gel was dried and subjected to autoradiography.
Supporting information
S1 Fig. Ectopic expression of ISG20 reduced HBV RNA in a dose dependent manner.
HepG2 cells in 12-well-plate were cotransfected with 1.2 μg of pHBV1.3 and variable amount
of plasmid F-ISG20 (as indicated), control vector was supplied to normalize the total plasmid
DNA in each transfection to 1.6 μg. Cells were harvest at day 5 posttransfection and the levels
of viral RNA were determined by Northern blot hybridization (top panel). Ribosomal RNAs
(28S and 18S) are presented as loading controls. The relative pgRNA level in each sample is
expressed as the percentage of RNA of the cells received no F-ISG20 (lane 1). ISG20 expression
was confirmed by Western blot using monoclonal antibody against FLAG tag. β-actin expres-
sion was presented as protein loading control (bottom panel).
(TIF)
S2 Fig. ISG20 overexpression is nontoxic to the cells. HepG2 cells in 96-well-plate were
transfected with control empty vector, or pHBV1.3, or pHBV1.3 plus F-ISG20. 5 days later,
cell viability was measured by CytoTox-ONE Homogeneous Membrane Integrity Assay, and
the relative cell viability values were plotted as percentage of the value from control samples
(mean±SD, n = 5).
(TIF)
S3 Fig. Antiviral effects of ISG20 on HBV surface mRNA and antigen production. (A)
ISG20 overexpression reduces the levels of HBV surface mRNA. HepG2 cells in 12-well-plate
were cotransfected with 0.8 μg of pLMS and 0.8 μg of control vector or plasmid F-ISG20. Four
days later, HBV surface mRNA (2.4 kb and 2.1 kb in length) were detected by Northern blot
hybridization. Results from duplicate experiments are presented. (B) ISG20 overexpression
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reduces the levels of viral antigens. HepG2 cells in 12-well-plate were cotransfected with 0.8 μg of
pHBV1.3 and 0.8 μg of control vector or plasmid F-ISG20. Four days later, the levels of HBeAg
and HBsAg in culture supernatant were measured by ELISA. The relative level of HBeAg and
HBsAg signals in each sample was plotted as the percentage of the signals from the control sam-
ples (mean ± SD, n = 4).
(TIF)
S4 Fig. ISG20 does not alter the levels of HBV RNA transcription template. (A) ISG20
overexpression does not reduce the level of transfected HBV plasmid DNA. HepG2 cells in
12-well-plate were cotransfected with 0.8 μg of plasmid pHBV1.3 and 0.8 μg of control vector
or plasmid F-ISG20. The cells were harvested at day 5 post transfection, total Hirt DNA was
treated by Dpn I and subjected to HBV DNA Southern blot (top panel). During cytoplasmic
HBV DNA extraction, DNase I digestion of input HBV plasmid DNA in cell lysates was omit-
ted, and the recovered cytoplasmic DNA samples were treated with Dpn I to digest the bacte-
ria-derived plasmid DNA with Dam methylation, but not the viral core DNA synthesized in
eukaryotic cells. The Dpn I-restricted pHBV1.3 DNA fragments migrated at the bottom of the
gel were revealed together with HBV core DNA by Southern blot using HBV probe (middle
panel). Expression of ISG20 was detected by Western blot with antibodies against FLAG-tag.
β-actin served as loading control. (B) Expression of ISG20 reduces HBV RNA in HBV stable
cell line. Tetracycline inducible (tet-off) HBV stable cell line HepDES19 cells, which tran-
scribes HBV RNA from the integrated HBV genome, were transfected with control vector or
plasmid F-ISG20 in tet-free medium. Four days later, HBV RNA and ISG20 expression were
analyzed by Northern and Western blot, respectively.
(TIF)
S5 Fig. ISG20 overexpression does not inhibit HBV promoter activity. HepG2 cells in
96-well-plate were co-transfected with reporter plasmid expressing luciferase under the con-
trol of HBV core promoter (EnII/Cp), or preS1 promoter (S1), or preS2/S promoter (S2), or
CMV-IE promoter, and control vector or plasmid F-ISG20. Cells were lysed two days post-
transfection and the relative luciferase activities was plotted as percentage of the luciferase
activity from each corresponding control samples (mean±SD, n = 3).
(TIF)
S6 Fig. ISG20D94G inhibits pgRNA encapsidation of a replication-defective HBV with poly-
merase Y63D mutation. Plasmid pCMVHBV-Y63D encodes a replication defective HBV
genome due to the mutation of priming site (Y63D) in viral polymerase TP domain, which,
upon transfection, arrests HBV replication at pgRNA encapsidation step without subsequent
reverse transcription. This plasmid was cotransfected into HepG2 cells with empty vector, or
F-ISG20, or F-ISG20D94G. 4 days later, viral total RNA, cytoplasmic capsid, encapsidated
pgRNA (capsid RNA), capsid DNA, and ISG20 expression were analyzed.
(TIF)
S7 Fig. ISG20-mediated HBV RNA degradation does not rely on viral core or pol protein.
The core-minus plasmid (pHBV1.3ΔC) or Pol-minus plasmid (pHBV1.3ΔP) was cotransfected
into HepG2 cells with either control empty vector or plasmid F-ISG20. 4 days later, HBV total
RNA was analyzed by Northern blot.
(TIF)
S8 Fig. The ISG20 responsive elements are not within the HBV pgRNA sequence between
two TRs. (A) Schematic illustrations of HBV clones that express pgRNA with internal
sequence deletions. The deleted regions of the internal deletion clones (pg-ID1 to pg-ID14)
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are between the indicated 5’ nucleotide positions and a fixed 3’ position at the second Rsr II
restriction site (nt1574). (B) Sensitivity of HBV pgRNA with internal sequence deletions to
ISG20-mediated RNA reduction. Plasmid pHBV1.3 and the internal deletion clones were
transfected into HepG2 cells individually with control plasmid or F-ISG20. Four days later,
viral RNA was analyzed by Northern blot.
(TIF)
S9 Fig. EMSA of HBV Pol:ε binding. (A) 3×FLAG-tagged HBV pol (3F-HP) was expressed
in rabbit reticulocyte lysate (RRL) through in vitro translation (IVT). The recombinant Pol
protein expression was confirmed by Western blot using FLAG antibody. (B) Control IVT
sample or 3F-HP IVT sample was incubated with 100 ng of 5’-radiolabeled ε RNA in TMNK
binding buffer, and the Pol-ε RNP complex was detected by EMSA.
(TIF)
S10 Fig. ISG20 does not associate with ZAP in cell cultures. HepG2 cells were mock trans-
fected (lane 1), or transfected with HA-ZAPS alone (lane 2), or cotransfected with F-ISG20
and HA-ZAPS (lane 3), or cotransfected with F-ISG20, HA-ZAPS, and pHBV1.3 (lane 4). Five
days later, the expression of F-ISG20 and HA-ZAPS was detected by Western blot using anti-
bodies against FLAG-tag and HA-tag, respectively, and β-actin served as loading control (top
panels). Then cell lysates were subjected to FLAG or HA immunoprecipitation (IP) and the
immunoprecipitated samples were subjected to Western blot (WB) assay with indicated anti-
bodies (bottom panels).
(TIF)
S1 Table. Sequence of synthetic RNA oligos.
(PDF)
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